The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients
Phase of Trial: Phase IV
Latest Information Update: 27 May 2016
Price : $35 *
At a glance
- Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Therapeutic Use
- 16 May 2016 Status changed from recruiting to completed.
- 16 Sep 2015 Interim results in 58 patients presented at 17th Congress of the European Society for Organ Transplantation.
- 16 Sep 2015 Status changed from not yet recruiting to recruiting, according to interim results presented at 17th Congress of the European Society for Organ Transplantation.